NCT06280495 2026-04-20
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Sun Yat-sen University
Phase 2/3 Recruiting
Sun Yat-sen University
Bristol-Myers Squibb
Jiangsu HengRui Medicine Co., Ltd.
Seattle Project Corporation
Centre Hospitalier Universitaire de Besancon
Shanghai Henlius Biotech
Bristol-Myers Squibb
Federation Francophone de Cancerologie Digestive
AstraZeneca
Sirtex Medical
National Cancer Institute (NCI)
Australasian Gastro-Intestinal Trials Group